CN110423814A - Elmo1基因甲基化检测试剂盒及其应用 - Google Patents
Elmo1基因甲基化检测试剂盒及其应用 Download PDFInfo
- Publication number
- CN110423814A CN110423814A CN201910654511.8A CN201910654511A CN110423814A CN 110423814 A CN110423814 A CN 110423814A CN 201910654511 A CN201910654511 A CN 201910654511A CN 110423814 A CN110423814 A CN 110423814A
- Authority
- CN
- China
- Prior art keywords
- elmo1
- gene
- gene methylation
- methylation
- detection kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 57
- 230000011987 methylation Effects 0.000 title claims abstract description 54
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 54
- 101100279558 Homo sapiens ELMO1 gene Proteins 0.000 title claims abstract description 36
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 34
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 32
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 10
- 238000003908 quality control method Methods 0.000 claims description 38
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 13
- 101150112014 Gapdh gene Proteins 0.000 claims description 12
- 230000007067 DNA methylation Effects 0.000 claims description 4
- 101150107722 Gfra1 gene Proteins 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 201000010989 colorectal carcinoma Diseases 0.000 abstract description 4
- 239000000090 biomarker Substances 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 47
- 108090000623 proteins and genes Proteins 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 27
- 238000012360 testing method Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 210000003608 fece Anatomy 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 238000012408 PCR amplification Methods 0.000 description 9
- 238000013461 design Methods 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 102100033423 GDNF family receptor alpha-1 Human genes 0.000 description 5
- 101000997961 Homo sapiens GDNF family receptor alpha-1 Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 102100027118 Engulfment and cell motility protein 1 Human genes 0.000 description 4
- 101001057862 Homo sapiens Engulfment and cell motility protein 1 Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 102100032191 Guanine nucleotide exchange factor VAV3 Human genes 0.000 description 3
- 101000775742 Homo sapiens Guanine nucleotide exchange factor VAV3 Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000004216 Glial cell line-derived neurotrophic factor receptors Human genes 0.000 description 1
- 108090000722 Glial cell line-derived neurotrophic factor receptors Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 101150030367 cls gene Proteins 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明发现了可以用于结直肠癌诊断的生物标志物,提供了一种可以用于结直肠癌检测的试剂,该试剂可以用于结直肠癌诊断的诊断中。本发明的ELMO1基因甲基化检测试剂盒,ELMO1基因甲基化检测试剂盒包含ELMO1基因甲基化特异性引物和ELMO1基因甲基化特异性荧光探针,ELMO1基因甲基化特异性引物为VAV3_F和VAV3_R,ELMO1_F序列如SEQ ID No.1:5’‑GTCGTCGGAGTTTTGATCGTC‑3’;ELMO1_R序列如SEQ ID No.2:5’‑CCCCTCCCCTACCGCGCCGA‑3’;ELMO1基因甲基化特异性荧光探针序列如SEQ ID No.3:5’‑AACGAATCGAAACGCGACGCCA‑3’。
Description
技术领域
本发明属于分子和细胞生物学领域,特别涉及基因甲基化检测。
背景技术
GDNF家族受体α-1(GFRα1),也被称为GDNF受体,是一种蛋白质,在人中由GFRA1基因编码,GFRA1被认为是原癌基因。
而结肠直肠癌(carcinoma of colon and rectum)胃肠道中常见的恶性肿瘤,早期症状不明显,随着癌肿的增大而表现排便习惯改变、便血、腹泻、腹泻与便秘交替、局部腹痛等症状,晚期则表现贫血、体重减轻等全身症状。其发病率和病死率在消化系统恶性肿瘤中仅次于胃癌、食管癌和原发性肝癌。
我国结直肠癌的发病率和死亡率均保持上升趋势。2015中国癌症统计数据显示我国结直肠癌发病率、死亡率在全部恶性肿瘤中均位居第5位,其中新发病例37.6万,死亡病例19.1万。其中,城市地区远高于农村,且结肠癌的发病率上升显著。近年来,随着人民生活水平的不断提高,饮食习惯和饮食结构的改变以及人口老龄化,我国结直肠癌(colorectalcancer,CRC)的发病率和死亡率均保持上升趋势。其中,结肠癌的发病率上升尤为显著。大多数患者发现时已属于中晚期。结肠直肠癌的早期筛查和诊断对结肠直肠癌的诊疗工作极为重要。
目前一些基于基于粪便甲基化基因检测的方法,进行结直肠癌早期筛查,目前已取得成就,证明其可以有效发现结直肠癌及其癌前病变,成功地为结直肠癌的防治提供一项新的技术。但目前可以用于检测位点仍不够丰富,检测位点较为单一。
发明内容
为进一步为结直肠癌诊疗提供可用的检测试剂,提高医疗机构结直肠癌诊疗水平,改善结直肠癌患者预后。
本发明发现了GFRA1基因甲基化与结直肠癌有关。我们发现,ELMO1基因甲基化与结直肠癌有关。我们测定了20例结直肠癌组织中ELMO1基因甲基化情况,结果20例结直肠癌组织中19例存在ELMO1基因甲基化,结直肠癌组织中ELMO1基因甲基化比例为95%。因而认为ELMO1基因甲基化可以作为用于结直肠癌诊断的生物标志物。该试剂盒可以用于结直肠癌诊断的诊断中。
根据本发明的一方面,提供了ELMO1基因甲基化检测试剂盒,ELMO1基因甲基化检测试剂盒包含ELMO1基因甲基化特异性引物和ELMO1基因甲基化特异性荧光探针,ELMO1基因甲基化特异性引物为VAV3_F和VAV3_R,
ELMO1_F序列如SEQ ID No.1:5’-GTCGTCGGAGTTTTGATCGTC-3’;
ELMO1_R序列如SEQ ID No.2:5’-CCCCTCCCCTACCGCGCCGA-3’;
ELMO1基因甲基化特异性荧光探针序列如SEQ ID No.3:
5’-AACGAATCGAAACGCGACGCCA-3’。
根据本发明的一方面,提供ELMO1基因甲基化检测试剂盒还包含内参基因GAPDH基因,的GAPDH基因的GAPDH基因甲基化特异性引物如下:
GAPDH_F序列如SEQ ID No.4:5’-TGGGGTGGTATAGTGGGGTGGTG-3’;
GAPDH_R序列如SEQ ID No.5:5’-CTACCCAACACCCCCAATCATAC-3’;
GAPDH基因甲基化特异性荧光探针如下:
GAPDH_P序列如SEQ ID No.6:5’-ACACTACCACCCACAATCTAAACACA-3’。
根据本发明的一方面,提供了ELMO1基因甲基化特异性荧光探针使用的荧光基团为FAM和BHQ1。
根据本发明的一方面,提供了ELMO1基因甲基化检测试剂盒还包含阳性质控品和阴性质控品,阳性质控品为经亚硫酸盐处理的甲基化人类基因组使用浓度为每微升的含量分别为:51.2ng,25.6ng,12.8ng,6.4ng,3.2ng,1.6ng,0.8ng,0.4ng,0.2ng,0.1ng,0.05ng,0.02ng,0.01ng,0.05ng,0.025ng,0.0125ng;阴性质控品为经亚硫酸盐处理的非甲基化人类基因组DNA使用浓度为每微升的含量分别为:51.2ng,25.6ng,12.8ng,6.4ng,3.2ng,1.6ng,0.8ng,0.4ng,0.2ng,0.1ng,0.05ng,0.025ng,0.0125ng。
根据本发明的一方面,提供了一种用于ELMO1基因甲基化检测试剂盒的应用,GFRA1基因甲基化检测试剂盒用于结直肠癌甲基化检测检测。
附图说明
图1、为本发明实施例中3个靶基因和内参基因的扩增曲线;
图2、为本发明实施例中是本发明涉及到的PCR扩增产物测序的结果;
具体实施方式
下述的实施例是为了进一步说明本发明的一些优选实施例,并非全部实施例。本领域专业人员在没有进行创造性劳动的前提下做出的基于本发明的其他实施例,都属于本发明的权利保护范围。下面将结合附图对本发明作进一步的说明。
1、PCR检测引物,靶基因引物和荧光探针序列为
2、PCR检测探针,内参基因引物和荧光探针序列为
具体判定标准如下表:
1)、阳性质控品内参基因PCR反应Ct值在36-42范围内且有明显指数扩增曲线,检测基因PCR反应Ct值在36-42范围内且有明显指数扩增曲线;阴性质控品内参基因PCR反应Ct值在36-42范围内且有明显指数扩增曲线,检测基因PCR反应无扩增曲线升起或Ct值大于45,实验有效。
2)、检测样品的内参PCR反应Ct值在36-42范围内且有明显指数扩增曲线,表明样品质量合格;若同时检测基因PCR反应Ct值在36-42范围内且有明显指数扩增曲线,则判断为阳性;若检测基因PCR反应无扩增曲线升起或Ct值大于45,则判断为阴性。
3)、若阳性质控品和/或阴性质控品内参基因PCR反应无扩增曲线升起或Ct值大于45;或者若阳性质控品检测基因PCR反应无扩增曲线升起或Ct值大于45,表明此次实验结果无效,建议更换试剂盒重新试验。
4)、若检测样品内参基因PCR反应无扩增曲线升起或Ct值大于45,表明样品质量不合乎要求,应重新收集样本提取DNA,并重新进行PCR检测。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1
DNA甲基化检测引物和荧光探针的设计,如下表:
GFRA1、VAV3、ELMO1为靶基因,GAPDH为内参基因。
如图1为3个靶基因和内参基因的扩增曲线;
如图2为涉及到的PCR扩增产物测序的结果;
实施例2DNA甲基化检测试剂盒分析灵敏度、特异度和最低检测限测试
1、材料与试剂
(1)靶基因的引物、荧光探针,内参基因的引物、荧光探针。如下表:
GFRA1、VAV3、ELMO1为靶基因,GAPDH为内参基因。
(2)进行荧光定量PCR所需的一般试剂:2xPCR反应液,无核酸酶纯净水,2xPCR反应液含有PCR反应缓冲液、Mg2+、和dNTPs。
(3)阳性质控品。阳性质控品为经亚硫酸盐处理的甲基化人类基因组DNA。按照定量结果稀释阳性质控品,使其每微升的含量分别为:51.2ng,25.6ng,12.8ng,6.4ng,3.2ng,1.6ng,0.8ng,0.4ng,0.2ng,0.1ng,0.05ng,0.02ng,0.01ng,0.05ng,0.025ng,0.0125ng。
(4)阴性质控品。阴性质控品为经亚硫酸盐处理的非甲基化人类基因组DNA。按照定量结果稀释阴性质控品,使其每微升的含量分别为:51.2ng,25.6ng,12.8ng,6.4ng,3.2ng,1.6ng,0.8ng,0.4ng,0.2ng,0.1ng,0.05ng,0.025ng,0.0125ng。
(5)以0.05ng阳性质控品作为检测样本。按比例混入经亚硫酸盐处理的非甲基化人类基因组DNA的经亚硫酸盐处理的甲基化人类基因组DNA,使其比例分别,0:1,1:1,2:1,4:1,8:1,16:1,32:1,64:1,128:1,256:1,512:1,1024:1和1:0。
2、仪器:上海宏石SLAN-96S全自动定量PCR仪、、离心机、涡旋仪、量程可调10ul、100ul、1000ul移液器、10ul 8道移液器、超净工作台和冰箱。
3、检测方法:
(1)PCR引物,荧光探针,PCR mix,纯水按照比例混合,分装为检测预混液,每反应管分装20ul
(2)检测反应:20ul 2xPCR反应液,加入5ul DNA样本+纯水
(3)仪器:上海宏石SLAN-96S全自动定量PCR仪
(4)PCR方法:预变性95℃10min,连接45个热循环反应95℃30秒,62℃30秒,72℃40秒
(5)进行荧光定量PCR扩增反应,读取各个PCR反应的CT值
4、检测结果
待测DNA标本为通过亚硫酸盐转化处理并纯化的阳性质控品、阴性质控品,及其按比例稀释或混合
荧光定量PCR扩增反应,扩增曲线应呈S型,自动分析确定基线。
检测结果如下表:
表1、实验01(阳性质控品PCR结果)
表2、实验02(阴性质控品PCR结果)
表3、实验03(检测样本PCR结果)
上述实验操作中,未注明具体条件的,均按照常规方法,例如《分子克隆实验指南》第四版进行或者按照制造厂商提供条件进行实验操作。
实验01,为梯度浓度的阳性对照品PCR结果,GAPDH基因Ct值从51.2ng到0.05ng显示出梯度效应,在0.05ng以下无PCR扩增信号;检测靶基因51.2ng到0.05ng可以确定有PCR扩增信号,且呈现出梯度效应,在0.05ng以下无PCR扩增信号。因而结果显示,试剂盒的最低检测限为0.05ng。
实验02,为梯度浓度的阴性对照品PCR结果,内参GAPDH基因Ct值从51.2ng到0.05ng显示出梯度效应,在0.05ng以下无PCR扩增信号;检测靶基因均无PCR扩增信号。结果显示,试剂盒的实验特异度为100%。
实验03,为模拟检测样本,是梯度浓度的阴性对照品+0.05ng阳性对照品。PCR结果,GAPDH基因在各个样本均有PCR扩增信号;检测靶基因Ct值在42-45之间,每个样本均有扩增信号。结果显示,试剂盒的分析灵敏度为1024:1。
实施例3
DNA甲基化检测试剂盒灵敏度、特异度、可重复性测试
1、材料与试剂
(1)检测反应液,内容为靶基因引物、靶基因荧光探针、内参基因引物、内参基因荧光探针。靶基因的引物、荧光探针,内参基因的引物、荧光探针的序列如下表:
GFRA1、VAV3、ELMO1为检测靶基因,GAPDH为内参基因
(2)进行荧光定量PCR所需的一般试剂:2xPCR反应液,无核酸酶纯净水。2xPCR反应液含有PCR反应缓冲液、Mg2+、dNTPs(包括dATP、dTTP、dCTP、dGTP)。
(3)阳性质控品1份、阴性质控品1份、正常人粪便DNA样品20份、结直肠癌患者粪便DNA样品20份(其中早期8例、中期8例、晚期4例)。阴性质控品为经亚硫酸盐处理的非甲基化人类基因组DNA;阳性质控品为经亚硫酸盐处理的甲基化人类基因组DNA。正常人粪便DNA样品为经结直肠镜检查无阳性发现的人的经亚硫酸盐处理的粪便DNA样品、结直肠癌患者粪便DNA样品为经结直肠镜检查确诊为结直肠癌的人的经亚硫酸盐处理的粪便DNA样品。
2、仪器:上海宏石SLAN-96S全自动定量PCR仪、离心机、涡旋仪、量程可调10ul、100ul、1000ul移液器、10ul 8道移液器、超净工作台和冰箱。
3、检测方法:
(1)将正常人粪便DNA样品、结直肠癌患者粪便DNA样品加入检测反应液、2xPCR反应液和纯水,一式三份配制PCR反应体系。
(2)将阳性质控品、阴性质控品加入检测反应液、2xPCR反应液和纯水配制PCR反应体系。
(3)将配制好的PCR体系放入实时定量PCR仪进行荧光定量PCR扩增反应。
4、结果判断方法
(a)阴性质控品:内参基因GAPDH有扩增信号,Ct值为34-42;靶基因无扩增信号。阳性质控品:内参基因GAPDH有扩增信号,Ct值为34-42;靶基因均有扩增信号,靶基因的Ct值在34-42。符合者表明实验可靠。
(b)正常人粪便DNA样品、结直肠癌患者粪便DNA(待测标本)的内参基因GAPDH有扩增信号,Ct值在34-42,表明待测标本合格。
(c)PCR反应的结果按照下表2进行判读:
表2
4、无效检测结果的处理方法
无效检测结果的判定方法如表2
无效检测结果的处理方法如表3
上述实验操作中,未注明具体条件的,均按照常规方法,例如分子克隆实验指南(第三版)进行或者按照制造厂商提供条件进行实验操作。
5、结果
实验01为可重复性检测,待测标本为0.1ng的阳性质控品,重复20次检测。
结果在实验01中,PC和NC质控品检测结果符合判定标准,待测标本GAPDH基因Ct值显示待测样本合格,实验有效。实验01共检测待测样品20个,均为0.1ng的阳性质控品,检测结果如下表4:
表4
由表4的结果可知,试剂盒的检测结果可信;20个0.1ng的阳性质控品靶基因检测结果均为阳性,试剂盒的可重复性为100%。
实验02为灵敏度检测,待测标本结直肠癌患者粪便DNA,共20例。
在实验02中,PC和NC质控品检测结果符合判定标准,待测标本GAPDH基因Ct值显示PCR扩增有效。实验02共检测样品20个,为结直肠癌患者粪便DNA样品,检测结果如下表5:
表5
由表5的结果可知,试剂盒的检测结果可信;20个结直肠癌患者粪便DNA样品靶基因检测结果均为阳性,试剂盒的灵敏性为100%。
实验03为特异度检测,待测标本正常人粪便DNA,共20例。
在实验03中,PC和NC质控品检测结果符合判定标准,待测标本GAPDH基因Ct值显示PCR扩增有效。实验批次03共检测样品20个,为正常人粪便DNA样品,检测结果如下表6:
表6
由表6的结果可知,试剂盒的检测结果可信;20个正常人粪便DNA样品中19个人的靶基因检测结果均为阴性,试剂盒的特异性为95%。
上述的实施例是为了进一步说明本发明的一些优选实施例,并非全部实施例。本领域专业人员在没有进行创造性劳动的前提下做出的基于本发明的其他实施例,都属于本发明的权利保护范围。
序列表
<110> 江苏元丞生物科技有限公司
<120> ELMO1基因甲基化检测试剂盒及其应用
<130> 2019
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<221>
<223> 根据检测基因设计
<400> 1
gtcgtcggag ttttgatcgt c 21
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221>
<223> 根据检测基因设计
<400> 2
cccctcccct accgcgccga 20
<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<221>
<223> 根据检测基因设计
<400> 3
aacgaatcga aacgcgacgc ca 22
<210> 4
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>
<223> 根据检测基因设计
<400> 4
tggggtggta tagtggggtg gtg 23
<210> 5
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>
<223> 根据检测基因设计
<400> 5
ctacccaaca cccccaatca tac 23
<210> 6
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<221>
<223> 根据检测基因设计
<400> 6
acactaccac ccacaatcta aacaca 26
Claims (5)
1.ELMO1基因甲基化检测试剂盒,其特征在于,所述ELMO1基因甲基化检测试剂盒包含ELMO1基因甲基化特异性引物和ELMO1基因甲基化特异性荧光探针,所述ELMO1基因甲基化特异性引物为VAV3_F和VAV3_R,
所述ELMO1_F序列如SEQ ID No.1:5’-GTCGTCGGAGTTTTGATCGTC-3’;
所述ELMO1_R序列如SEQ ID No.2:5’-CCCCTCCCCTACCGCGCCGA-3’;
所述ELMO1基因甲基化特异性荧光探针序列如SEQ ID No.3:
5’-AACGAATCGAAACGCGACGCCA-3’。
2.根据权利要求1所述的ELMO1基因甲基化检测试剂盒,其特征在于,所述ELMO1基因甲基化检测试剂盒还包含内参基因GAPDH基因,所述的GAPDH基因的GAPDH基因甲基化特异性引物如下:
GAPDH_F序列如SEQ ID No.4:5’-TGGGGTGGTATAGTGGGGTGGTG-3’;
GAPDH_R序列如SEQ ID No.5:5’-CTACCCAACACCCCCAATCATAC-3’;
GAPDH基因甲基化特异性荧光探针如下:
GAPDH_P序列如SEQ ID No.6:5’-ACACTACCACCCACAATCTAAACACA-3’。
3.根据权利要求2所述的ELMO1基因甲基化检测试剂盒,其特征在于,所述ELMO1基因甲基化特异性荧光探针使用的荧光基团为FAM和BHQ1。
4.根据权利要求1至3所述的ELMO1基因甲基化检测试剂盒,其特征在于,所ELMO1基因甲基化检测试剂盒还包含阳性质控品和阴性质控品,所述的阳性质控品为经亚硫酸盐处理的甲基化人类基因组使用浓度为每微升的含量分别为:51.2ng,25.6ng,12.8ng,6.4ng,3.2ng,1.6ng,0.8ng,0.4ng,0.2ng,0.1ng,0.05ng,0.02ng,0.01ng,0.05ng,0.025ng,0.0125ng;所述阴性质控品为经亚硫酸盐处理的非甲基化人类基因组DNA使用浓度为每微升的含量分别为:51.2ng,25.6ng,12.8ng,6.4ng,3.2ng,1.6ng,0.8ng,0.4ng,0.2ng,0.1ng,0.05ng,0.025ng,0.0125ng。
5.一种用于GFRA1基因甲基化检测试剂盒的应用,其特征在于,所述ELMO1基因甲基化检测试剂盒用于结直肠癌甲基化检测检测。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910654511.8A CN110423814A (zh) | 2019-07-19 | 2019-07-19 | Elmo1基因甲基化检测试剂盒及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910654511.8A CN110423814A (zh) | 2019-07-19 | 2019-07-19 | Elmo1基因甲基化检测试剂盒及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110423814A true CN110423814A (zh) | 2019-11-08 |
Family
ID=68410184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910654511.8A Pending CN110423814A (zh) | 2019-07-19 | 2019-07-19 | Elmo1基因甲基化检测试剂盒及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110423814A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110616263A (zh) * | 2019-09-27 | 2019-12-27 | 江苏元丞生物科技有限公司 | 多位点结直肠癌甲基化检测试剂盒 |
CN112646891A (zh) * | 2020-12-30 | 2021-04-13 | 苏州唯善生物科技有限公司 | 消化道肿瘤标志物组合、检测试剂盒及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120178634A1 (en) * | 2009-07-03 | 2012-07-12 | Sysmex Corporation | Method for determination of presence of cancer cell, and method for determination of prognosis of cancer patient |
US20170058356A1 (en) * | 2015-08-31 | 2017-03-02 | Mayo Foundation For Medical Education And Research | Detecting gastric neoplasm |
US20170298439A1 (en) * | 2016-04-14 | 2017-10-19 | Mayo Foundation For Medical Education And Research | Detecting colorectal neoplasia |
US20170356051A1 (en) * | 2014-10-17 | 2017-12-14 | Tohoku University | Method for estimating sensitivity to drug therapy for colorectal cancer |
-
2019
- 2019-07-19 CN CN201910654511.8A patent/CN110423814A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120178634A1 (en) * | 2009-07-03 | 2012-07-12 | Sysmex Corporation | Method for determination of presence of cancer cell, and method for determination of prognosis of cancer patient |
US20170356051A1 (en) * | 2014-10-17 | 2017-12-14 | Tohoku University | Method for estimating sensitivity to drug therapy for colorectal cancer |
US20170058356A1 (en) * | 2015-08-31 | 2017-03-02 | Mayo Foundation For Medical Education And Research | Detecting gastric neoplasm |
US20170298439A1 (en) * | 2016-04-14 | 2017-10-19 | Mayo Foundation For Medical Education And Research | Detecting colorectal neoplasia |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110616263A (zh) * | 2019-09-27 | 2019-12-27 | 江苏元丞生物科技有限公司 | 多位点结直肠癌甲基化检测试剂盒 |
CN112646891A (zh) * | 2020-12-30 | 2021-04-13 | 苏州唯善生物科技有限公司 | 消化道肿瘤标志物组合、检测试剂盒及其用途 |
WO2022143226A1 (zh) * | 2020-12-30 | 2022-07-07 | 苏州唯善生物科技有限公司 | 消化道肿瘤标志物组合、检测试剂盒及其用途 |
CN112646891B (zh) * | 2020-12-30 | 2023-09-05 | 苏州唯善生物科技有限公司 | 消化道肿瘤标志物组合、检测试剂盒及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ouyang et al. | Noninvasive testing for colorectal cancer: a review | |
Majumder et al. | Methylated DNA in pancreatic juice distinguishes patients with pancreatic cancer from controls | |
WO2022022386A1 (zh) | 早期结直肠癌和腺瘤的dna甲基化标志物、检测其的方法及其应用 | |
CN110331142B (zh) | 一种多基因联合检测试剂 | |
CN111778332A (zh) | 一种用于腺瘤及结直肠癌早期诊断的标志物组合及试剂盒 | |
CN110317871B (zh) | 一种基因标志物组合及其应用 | |
CN110423814A (zh) | Elmo1基因甲基化检测试剂盒及其应用 | |
CN107904313A (zh) | 用于胃癌相关基因Reprimo、RNF180甲基化检测的引物对、试剂盒及方法 | |
WO2023226938A1 (zh) | 甲基化生物标记物、试剂盒及用途 | |
CN108866196A (zh) | 一种用于人结直肠肿瘤特异性甲基化检测的引物和探针、试剂盒及其应用 | |
CN116121380A (zh) | 一种用于检测膀胱癌相关基因的引物探针组合及检测方法 | |
EP4047101A1 (en) | Primer set for methylation of a specific region of a human colorectal cancer-related gene, test, test kit and application thereof | |
CN110283910A (zh) | 目标基因dna甲基化作为分子标志物在制备判别结直肠组织癌变进展试剂盒中的应用 | |
CN110951872A (zh) | 一种基于核酸质谱技术检测结直肠癌基因dna甲基化水平的方法及其应用 | |
CN110317874A (zh) | Vav3基因甲基化检测试剂盒及其应用 | |
CN110408700A (zh) | Gfra1基因甲基化检测试剂盒及其应用 | |
CN106048021A (zh) | 用于检测微量组织中p53基因突变的引物组合及其应用 | |
CN107641649B (zh) | 检测微卫星nr27位点稳定性的引物对、试剂盒及方法 | |
CN108179195A (zh) | 一种结直肠癌超早期病变检测的试剂盒、方法及其应用 | |
CN111826446A (zh) | 用于膀胱癌早期筛查与辅助诊断的引物、探针和试剂盒 | |
CN105463115A (zh) | 用于检测人类ret基因7种突变的探针、引物及试剂盒 | |
CN109097468A (zh) | Opcml基因启动子甲基化水平的检测试剂盒及其应用 | |
CN110616263A (zh) | 多位点结直肠癌甲基化检测试剂盒 | |
CN111850129B (zh) | 检测微卫星nr21位点稳定性的引物对、试剂盒及方法 | |
CN116064786A (zh) | 一种用于检测胃癌的组合物,试剂盒及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191108 |